Pulse Biosciences, Inc.
52.97USD
+4.1800 (+8.57%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 700.0K | 0.0 | 0.0 | 350.0K | 2.0M | 7.9M |
| Q1 | 444.0K | 0.0 | 0.0 | 0.0 | 401.0K | — |
| Q2 | 265.0K | 0.0 | 0.0 | 0.0 | 434.0K | — |
| Q3 | 0.0 | 0.0 | 0.0 | 86.0K | 500.0K | — |
| Q4 | -9.0K* | 0.0* | 0.0* | 264.0K* | 666.7K | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.72 | -.850 | -.920 | -1.08 | -1.10 | -1.16 |
| Q1 | -.580 | -.260 | -.180 | -.250 | -.270 | — |
| Q2 | -.440 | -.220 | -.200 | -.280 | -.360 | — |
| Q3 | -.490 | -.190 | -.210 | -.290 | -.295 | — |
| Q4 | -.220* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.210* |
| -.320* |
| -.260* |
| -.295 |
| — |